Europe Single-use Bioreactors Market (2025-2032)
The Europe Single-use Bioreactors Market is projected to reach $3.34 billion by 2032, at a CAGR of 15.3% from 2025 to 2032.
- Published
- Jan 2025
- Pages
- 150
- Format
- PDF + Excel
- Report ID
- MRHC - 104869
- Base year
- 2024
- 2032 · FORECAST
- $3.34B
- 2032
- $3.34B
- CAGR 2025–2032
- 15.3%
2024 baseline · 2025–2032 forecast at 15.3% CAGR · hover a bar for the value
Key highlights
Among Products, the Media Bags Segment is Projected to Register the Highest CAGR
Among Types, the Wave-induced Bioreactors Segment is Projected to Register the Highest CAGR
Among Cell Types, in 2025, the Mammalian Cells Segment is Expected to Account for the Largest Share
The Research Bio-production Segment is Projected to Register the Highest CAGR
Germany: In 2025, to Account for the Largest Share of the Market
Report summary
| Particulars | Details |
|---|---|
| Base Year | 2024 |
| Estimated Year | 2025 |
| Forecast Period | 2025–2032 |
| Market Size (2032) | USD 3.34 billion |
| CAGR (2025–2032) | 15.3% |
| Format | PDF, Excel & Cloud Portal · 150 pages |
| Segments Covered | By Product: Single-use Bioreactor Systems Upto 10L, 11L-500L, 501-1000L, Above 1001L, 2D, 3D, Linear · By Type: Stirred-tank Bioreactors, Wave-induced Bioreactors, Other Types · By Cell Type: Mammalian cells, Bacterial Cells, Yeast Cells, Other Cell Types · By Application: Commercial Bioproduction Monoclonal Antibody Production, Vaccine Production, Therapeutic Protein Production, Cell & Gene Therapy · By End User: Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes · By Cell: Mammalian, Bacterial, Yeast |
| Countries Covered | Europe (Germany, U.K., France, Italy, Switzerland, Ireland, Denmark, Belgium, Spain, Rest of Europe) |
| Key Companies | Merck KGaA, Danaher Corporation, Sartorius AG, Thermo Fisher Scientific Inc., Eppendorf AG, Cellexus International Ltd., CESCO Bioengineering Co., Ltd., PBS Biotech, Inc., Solida Biotech GmbH, Infors AG |
Report overview
Segments covered: product, type, cell type, application, end user, cell. Regions: Europe.
Single-use bioreactors, also called disposable bioreactors, are made of disposable bags instead of a culture vessel. These bioreactors eliminate the need for expensive and bulky clean-in-place (CIP) or steam-in-place (SIP) systems and offer flexibility and a low risk of contamination, contributing to their adoption by pharma & biotech companies. Along with this, end users' manufacturing and R&D capacity expansion increases the demand for the products in the region. For instance, in September 2022, Viralgen Vector Core (Viralgen), a member of the Bayer worldwide group of companies, received Certified Good Manufacturing Practices (cGMP) certification for human medicinal products, investigational medicinal products, and sterile or biologically active substances.
The rapid adoption of disposable technology in the pharmaceutical and biotechnology industry, growing demand for biopharmaceuticals, government support for the production & use of biopharma products for various health indications, and capacity expansion of biopharmaceutical plants are some of the major factors driving the growth of the Europe single-use bioreactors market.
Report infographic
Market dynamics
1 factors across 1 forceGovernment Initiatives to Increase Bioproduction is an Opportunity for the Players in this Market
European governments are investing in the pharma & biopharma industry to boost R&D and bioproduction. The government and other public groups and enterprises are providing funding and grants for research and development to pharmaceutical, biopharmaceutical, and biotech companies, thereby helping to grow the biopharmaceutical market and increasing demand for single-use bioreactors. For instance,
- In 2021, the U.K. Biotechnology and Biological Sciences Research Council (BBSRC), which provides USD 101 million (GBP 57 million) each year for R&D in biotechnology and biological sciences, has adopted a new strategy for investment. Along with this strategy, the U.K. government aims to increase R&D spending to 2.4% of gross domestic product by 2027.
- In 2021, the Government of Ireland allocated USD 975.2 billion (EUR 869.2 billion) for research and development to software, medical devices, manufacturing, and pharmaceutical companies.
- In 2021, the Prime Minister of the U.K. hosted an event with large biopharmaceutical companies, including AstraZeneca (U.K.), GlaxoSmithKline (U.K.), and Pfizer (U.K.), to strengthen future pandemic responses. This summit was after announcing new investments, which swooped in USD 6.7 billion (GBP 5 billion) from July 2021 to December 2021.
- In 2021, the Irish government provided funding of USD 4.9 billion (EUR 4 billion) for R&D to ICON plc (Ireland), a drug development solutions and services provider to the pharmaceutical, biotechnology, and medical device industries. This funding was awarded for clinical trials to expand patient access to clinical research through technology.
Table of contents
13 chapters · 86 sections · 150 pages · click to expandSegmental analysis
| Segment | Largest share (2025) | Fastest growth (2025–2032) |
|---|---|---|
| By Product | — | — |
| By Type | — | — |
| By Cell Type | Mammalian Cells | — |
| By Application | Pharmaceutical & Biopharmaceutical Companies | Research bio-production |
By Product
- The Media Bags Segment is Projected to Register the Highest CAGR
- Advantages like high flexibility, low levels of extractable and leachable and high product stability during storage compared to culture vessels supported the market growth.
- Also, the low risk of cross-contamination from batch to batch and product to product and eliminating the time and expense of sterilization-in-place (SIP) & clean-in-place (CIP) operations, optimizing capacity utilization, increase their adoption for bioprocessing.
By Type
- The Wave-induced Bioreactors Segment is Projected to Register the Highest CAGR
- Wave-induced bioreactor systems offer various benefits, like no need to rely on oxygen bubbles for culture aeration, generation of rocking motion to meet the required amount of oxygen for cell growth, and a large surface-to-volume ratio.
- These benefits lead to driving the market at the highest growth rate.
- In contrast to conventional stirred tank bioreactors, wave-induced bioreactor systems improve fluid turnover and minimize shear forces compared to stirred tanks.
- Such flow conditions reportedly produce better cell suspension and reduce the risk of cell damage and thus have enabled rocking-motion bioreactors to reach higher maximum cell densities than traditional spinner flasks.
By Cell Type
- The mammalian cells segment is expected to account for the largest share of the market.
- Increased need for mAbs production with consistent quality and preference for culturing in large-scale suspension bioreactors to increase bioproduction supported the share.
- Also, Demand for high throughput operations in cell culture processing will continue to drive the single-use bioreactor market for mammalian cells.
By Application
- The research bio-production segment is projected to register the highest CAGR owing to growing support from regulatory agencies & companies’ initiatives.
- For instance, in January 2021, the Circa Group Europe Limited (Ireland) invested USD 2.2 billion (EUR 2 billion) in biopharmaceutical research and development through IDA Ireland’s client companies annually.
- Thus, such an investment plan helps boost the demand for biopharma products in the European region, thereby driving the market.
- The Pharmaceutical & Biopharmaceutical Companies Segment is Expected to Account for the Largest Share of the Market
- The large market share of this segment is attributed to the rise in R&D activities, the focus of U.S.-based companies to expand their manufacturing capacities in European countries, the high adoption of bioreactors in pharmaceutical laboratories, and concerns over flexibility, sterility, cost efficiency, and enhanced productivity.
- Also, increasing demand for biopharmaceutical products, growing adoption of single-use products, growing incidence & prevalence of various chronic diseases, rising R&D expenditure by pharmaceutical & biotechnology companies, and recent launches of biologics for chronic & rare diseases raise the growth of the market for them.
Geographic analysis
Europe
Largest shareThe factors supporting the large share of this market include increasing pharmaceutical export, government grants, growth in immunization, and funding to biotech & biopharmaceutical companies expanding their capacities for biologics to meet the market's increasing demand. Being one of the largest biopharma markets in the EU region and the presence of key players in the country supported their large share in the market. Germany: In 2025, to Account for the Largest Share of the Market
Competitive landscape
- Merck KGaA
- Danaher Corporation
- Sartorius AG
- Thermo Fisher Scientific Inc.
- Eppendorf AG
- Cellexus International Ltd.
- CESCO Bioengineering Co., Ltd.
- PBS Biotech, Inc.
- Solida Biotech GmbH
- Infors AG
Frequently asked questions
This study offers a detailed assessment of the Europe single-use bioreactors market, including the market size & forecast for various segmentations, including product, type, cell type, application, and end user. The Europe single-use bioreactors market studied in this report also involves the value analysis of various segments and sub-segments of single-use bioreactors at country levels.
Cite this report
Meticulous Research. (2025). Europe Single-use Bioreactors Market - Opportunity Analysis and Industry Forecast (2025-2032) (Report No. MRHC - 104869). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/europe-single-use-bioreactors-market-5552